HC Wainwright Analysts Lower Earnings Estimates for MindWalk

MindWalk Holdings Corp. (NASDAQ:HYFT) – Equities research analysts at HC Wainwright cut their Q1 2027 earnings estimates for shares of MindWalk in a note issued to investors on Thursday, July 23rd. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($0.05) per share for the quarter, down from their previous forecast of ($0.04). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for MindWalk’s current full-year earnings is ($0.21) per share. HC Wainwright also issued estimates for MindWalk’s Q3 2027 earnings at ($0.06) EPS, Q4 2027 earnings at ($0.06) EPS, FY2027 earnings at ($0.21) EPS, FY2028 earnings at ($0.17) EPS, FY2029 earnings at ($0.09) EPS and FY2030 earnings at $0.01 EPS.

MindWalk (NASDAQ:HYFT) last posted its quarterly earnings results on Wednesday, July 22nd. The company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.01). MindWalk had a negative return on equity of 92.61% and a negative net margin of 89.65%.The business had revenue of $3.03 million for the quarter.

Other analysts have also recently issued research reports about the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of MindWalk in a research report on Wednesday, July 15th. JonesTrading initiated coverage on MindWalk in a research report on Thursday, April 16th. They issued a “buy” rating and a $5.00 price target on the stock. Finally, Wall Street Zen cut MindWalk from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, MindWalk presently has an average rating of “Moderate Buy” and an average target price of $5.00.

MindWalk Stock Performance

Shares of HYFT stock opened at $1.36 on Monday. The firm has a 50 day simple moving average of $1.56. The company has a current ratio of 2.80, a quick ratio of 2.72 and a debt-to-equity ratio of 0.26. MindWalk has a 52-week low of $0.99 and a 52-week high of $3.25. The company has a market capitalization of $63.53 million, a PE ratio of -6.18 and a beta of 0.83.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Virtu Financial LLC acquired a new position in MindWalk during the fourth quarter valued at approximately $51,000. Bridgeway Capital Management LLC acquired a new stake in MindWalk in the fourth quarter worth $91,000. Bank of Montreal Can raised its holdings in MindWalk by 81.0% in the fourth quarter. Bank of Montreal Can now owns 54,750 shares of the company’s stock worth $100,000 after purchasing an additional 24,500 shares during the period. XTX Topco Ltd boosted its position in shares of MindWalk by 118.6% during the fourth quarter. XTX Topco Ltd now owns 81,721 shares of the company’s stock worth $149,000 after purchasing an additional 44,331 shares in the last quarter. Finally, Jane Street Group LLC boosted its position in shares of MindWalk by 147.3% during the fourth quarter. Jane Street Group LLC now owns 161,202 shares of the company’s stock worth $293,000 after purchasing an additional 96,018 shares in the last quarter. Institutional investors own 6.70% of the company’s stock.

Key Headlines Impacting MindWalk

Here are the key news stories impacting MindWalk this week:

• Positive Sentiment: HC Wainwright maintained a Buy rating on MindWalk and the broader brokerage view remains Moderate Buy, suggesting Wall Street still sees upside potential despite near-term losses. MindWalk Holdings Corp. (NASDAQ:HYFT) Given Consensus Rating of “Moderate Buy” by Brokerages
• Neutral Sentiment: MindWalk’s latest earnings call highlighted the company’s growth efforts, but the business is still posting persistent losses, keeping investor focus on the path to profitability. MindWalk Holdings Charts Growth Amid Persistent Losses
• Negative Sentiment: HC Wainwright cut earnings estimates across multiple periods, including FY2027, FY2028, FY2029, and FY2030, signaling a weaker profit outlook and pressuring the stock. Brokers Issue Forecasts for MindWalk FY2031 Earnings
• Negative Sentiment: Another analyst report from Wall Street Zen lowered its rating on HYFT, adding to concerns that recent expectations may be too optimistic. MindWalk (NASDAQ:HYFT) Stock Rating Lowered by Wall Street Zen

About MindWalk

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, engages in antibody production and related services in the United States, Canada, Europe, and internationally. The company offers a range of antibodies, enzymes, enzyme activity assays, arthritis animal products, proteins, deiminated proteins, organoid growth factors, and hybridoma products for research purposes. Its services include custom antigen modeling, design, and manufacturing; B cell sorting, screening, and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multi-species antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing; antibody characterization on label-free biosensors and antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with multiplexed, high-throughput screening, and clone-picking; and cryopreservation.